期刊文献+

2型糖尿病肾病患者血清胱抑素的对照分析与临床检验学研究

下载PDF
导出
摘要 目的研究分析血清胱抑素C检测在不同程度2型糖尿病肾病患者中的应用价值,并观察厄贝沙坦对其的影响。方法选择340例2型糖尿病患者,并以72例健康人作为对照,分别测定血清胱抑素C(Cys-C)、血肌酐(Cr)、尿素氮(BUN)水平。将340例2型糖尿病患者根据血肌酐水平细化分为A、B两组,然后分别给予厄贝沙坦150 mg/d服用,8周后重复测量上述指标。结果 2型糖尿病肾病患者中血清Cys-C和血肌酐(Cr)、尿素氮(BUN)较正常对照组明显升高(P<0.01)。经厄贝沙坦治疗后,在A组中血清Cys-C和血肌酐(Cr)、尿素氮(BUN)均明显下降(P<0.01,P<0.05),B组中血清Cys-C水平下降(P<0.05),血肌酐(Cr)、尿素氮(BUN)无明显变化。结论血清Cys-C可以作为2型糖尿病肾病肾功能损害早期的诊断指标之一,厄贝沙坦可以降低血清Cys-C水平,延缓肾功能损害。
作者 孙素媛
出处 《中国医药指南》 2016年第33期72-73,共2页 Guide of China Medicine
  • 相关文献

参考文献2

二级参考文献19

  • 1顾春瑜,郑磊,王前.血清胱抑素C在评价肾移植患者肾功能中的应用[J].国外医学(临床生物化学与检验学分册),2004,25(6):559-561. 被引量:64
  • 2Pitt B,Segal R.Martinez FA,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).Lancet, 1997,349:747-752.
  • 3Pitt B,Poole-Wilson PA,Segal R,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.Lancet, 2000,355:1582-1587.
  • 4Daholof B,Devereux RB,Kjeldsen SE,et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet,2002,359:995-1003.
  • 5Lewis EJ,Hunsicker LG,Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med, 2001,345:851-860.
  • 6Circulation, 2002;106:672.
  • 7Parving HH,Lehnert H,Brochner-Mortensen J,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med, 2001,345:870-878.
  • 8Brenner BM,Cooper ME,de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med. 2001 Sep 20;345(12):861-869.
  • 9Lithell H,Hansson L,Skoog I,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.J Hypertens, 2003,21:875-886.
  • 10ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Groop. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lo

共引文献128

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部